Ibrance and Gastrointestinal arteriovenous malformation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal arteriovenous malformation is found among people who take Ibrance, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Ibrance and have Gastrointestinal arteriovenous malformation. It is created by eHealthMe based on reports of 79,191 people who have side effects when taking Ibrance from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Apr, 02, 2023

79,191 people reported to have side effects when taking Ibrance.
Among them, 7 people (0.01%) have Gastrointestinal arteriovenous malformation.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 79,275 Ibrance users for its effectiveness, alternative drugs and more.

What is Gastrointestinal arteriovenous malformation?

Gastrointestinal arteriovenous malformation (malformation of arteries and veins in gastrointestinal tract) is found to be associated with 420 drugs and 175 conditions by eHealthMe.

Number of Ibrance and Gastrointestinal arteriovenous malformation reports submitted per year:

Could Ibrance cause Gastrointestinal arteriovenous malformation?

Gender of people who have Gastrointestinal arteriovenous malformation when taking Ibrance *:

female: 100 %
male: 0.0 %

Age of people who have Gastrointestinal arteriovenous malformation when taking Ibrance *:

Common drugs people take besides Ibrance *:

Amlodipine: 7 people, 100.00%
Zometa: 3 people, 42.86%

Common side effects people have besides Gastrointestinal arteriovenous malformation *:

Gastric Haemorrhage (bleeding stomach): 7 people, 100.00%
Urinary Tract Infection: 7 people, 100.00%
Renal Impairment (severely reduced kidney function): 6 people, 85.71%
Blood Count Abnormal: 4 people, 57.14%
Tumor Marker Increased: 4 people, 57.14%
Sinus Headache (headache caused by sinus infections): 4 people, 57.14%
Hypersensitivity: 4 people, 57.14%
Depression: 3 people, 42.86%
Gastric Ulcer (stomach ulcer): 3 people, 42.86%
Weight Increased: 3 people, 42.86%

Common conditions people have *:

Breast Cancer Metastatic: 5 people, 71.43%
High Blood Pressure: 3 people, 42.86%
Breast Cancer Female: 3 people, 42.86%
Bone Loss: 3 people, 42.86%
Breast Cancer: 2 people, 28.57%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and have Gastrointestinal arteriovenous malformation?

Check whether Gastrointestinal arteriovenous malformation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Gastrointestinal arteriovenous malformation and when was it recovered:

Gastrointestinal arteriovenous malformation in Ibrance

Expand to all the drugs that have ingredients of palbociclib:

Gastrointestinal arteriovenous malformation and drugs with ingredients of palbociclib

Alternative drugs to, pros and cons of Ibrance:

Ibrance (79,275 reports)

Common Ibrance side effects:

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Gastrointestinal arteriovenous malformation treatments and more:

Gastrointestinal arteriovenous malformation (423 reports)

COVID vaccines that are related to Gastrointestinal arteriovenous malformation:

All the drugs that are associated with Gastrointestinal arteriovenous malformation:

Gastrointestinal arteriovenous malformation (420 drugs)

All the conditions that are associated with Gastrointestinal arteriovenous malformation:

Gastrointestinal arteriovenous malformation (175 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.